An interventional study of inhalation management education in Chronic Obstructive Lung Disease, sponsored by Kumamoto University. Not yet recruiting at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2025-12-31.
Sponsored by Kumamoto University · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 108 studies in Pulmonary Disease, Chronic Obstructive with a site in Japan — 13 open to participants now, 16 under way, 8 of them phase 3. Pulmonary Disease, Chronic Obstructive · Japan.
Among the 108 studies in Pulmonary Disease, Chronic Obstructive with a site in Japan, this one is the 74th largest by planned enrollment of the 88 interventional ones that give a count, is one of 4 that started in 2026, is one of 6 with no phase, reaches primary completion later than 1 of the 15 other live ones, and was the 103rd registered.
5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →13 of the 108 studies in Pulmonary Disease, Chronic Obstructive with a site in Japan are open now. Recruiting first, the newest first:
GlaxoSmithKline · Sites in Japan, United States
Ages 40–80
Eli Lilly and Company · Sites in Japan, United States, Argentina and 15 more countries
Ages 40–75
Pfizer · Sites in Japan, United States, Argentina and 15 more countries
Ages 35–80
GlaxoSmithKline · Sites in Japan, United States, Argentina and 22 more countries
Ages 40–75
Sanofi · Sites in Japan, United States, Argentina and 19 more countries
Ages 40–85
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
108 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 16 · Phase 3 55 · Phase 4 6
First in 2002; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is close to the median of 62 across 3,847 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 619 across the 88 interventional studies, 709 across the 20 observational. Of the 92 that completed or were terminated, 58 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
103 of 108 have an industry lead sponsor. The 10 most frequent:
Kumamoto University is the lead sponsor of 23 studies on the registry; 1 is open to participants now.
Kumamoto University has 1 study filed under Pulmonary Disease, Chronic Obstructive — fewer than ten, so there is no comparison to draw.
6 of the studies in Pulmonary Disease, Chronic Obstructive with a site in Japan that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05878769Phase 3Hoffmann-La RocheA Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) | 2027-06-30 |
| NCT07311499Kumamoto UniversityImprovement of Sleep in COPD Patients Through Inhalation Management Education by Nurse. | 2026-12 |
| NCT06712563AstraZenecaPooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting | 2026-12-14 |
| NCT07108166Philip Morris Products S.A.Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS | 2027-02 |
| NCT06332885Pulmonx CorporationZephyr Valve Japan Post-Marketing Surveillance | 2027-03-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 108 studies in Pulmonary Disease, Chronic Obstructive with a site in Japan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to investigate whether inhalation management education provided by nurses improves sleep quality in patients with COPD. Inhalation management education includes training in inhalation techniques and guidance on how to use medications when symptoms occur.
The main research question is:
・Does inhalation management education improve sleep quality in patients with COPD?
Researchers will determine whether inhalation management education improves sleep quality compared to no education.
Participants will:
●Research participants, eligibility criteria, and exclusion criteria The study will include stable COPD patients who are outpatients at Kumamoto University Hospital, Kounan Hospital, or Iwakuni City Nishiki Central Hospital, which specialize in internal and respiratory medicine. Eligible participants must meet all of the following criteria and must not meet any exclusion criteria.
【Eligibility Criteria】
【exclusion criterias】
Diagnosis of dementia or other psychiatric disorders.
Following the pre-established random allocation table, participants will be sequentially assigned to each treatment group in the order of case registration, and a registration confirmation form will be issued, indicating the participant's registration number and treatment group. The allocation table will be retained by the allocation officer and will not be disclosed to the principal investigator or co-investigators.
●Sample size Target number of participants (Total: 34 cases) Intervention group: 17 cases Control group: 17 cases Number of participants expected to enroll(Total: 60 cases) Intervention group: 30 cases Control group: 30 cases There are no previous studies measuring the effect of inhalation management education on sleep quality. In previous studies, the average PSQI score for COPD patients was 8.3-11.5 points, and the PSQI cutoff value is 5.5 points. Assuming a change of 5.0 points in the average PSQI-J score after 3 months in the intervention group, the sample size required to maintain a two-sided test (significance level 5%) with 80% power is 17 cases per group. Considering that many participants are elderly and may have difficulty continuing to use computers or video conferencing tools, a higher dropout rate than usual is anticipated. Therefore, 30 participants per group, totaling 60 participants, will be enrolled in the study.
●Criteria for exclusion from analysis The definition of the analysis population is as follows.
-Full Analysis Set (FAS) The FAS consists of all study subjects who provided informed consent, excluding the following study subjects.
The PPS is defined as the FAS excluding the following subjects:
This study will clearly identify the breakdown of cancellations and dropouts by compiling data on the number of registered subjects who were excluded from the analysis population and the reasons for their exclusion, broken down by analysis population.
●Analysis and statistical methods for verifying evaluation items Statistical analysis will be performed using JMP Pro 18, with a significance level set at 5%.
-Analysis of primary endpoints Primary endpoint: Change in PSQI-J at 3 months before and after the educational intervention The primary endpoint will be analyzed using the FAS. The change in PSQI-J scores will be calculated for each group, and independent t-tests will be performed to compare groups at a significance level (two-sided) of 5%. A similar analysis will be conducted using PPS as the analysis population as a secondary analysis.
-Using FAS as the analysis population, the difference in the mean change in JESS, Japanese CAT, and HADS scores between groups will be analyzed using a paired t-test at a significance level of 5%. Similar analyses will also be conducted using PPS as the analysis population.
In this study, baseline data for the primary outcome measure, PSQI, were missing at study registration. If PSQI-J was measured within one month of baseline (prior to the first intervention), that data was used to impute baseline data for PSQI-J. This method of data imputation may result in the presence of data from different measurement time points at baseline.
However, since the PSQI-J reflects sleep quality over the past month and no interventions were conducted during that period, this method of data supplementation is considered appropriate. For other items, missing values will not be supplemented.
Information on patients obtained at baseline from participants who withdrew from the study or withdrew their consent will be used for analysis if consent is obtained from the participants themselves, as it constitutes valuable data on inhalation techniques, inhalation education, and methods for current COPD patients.
●Criteria for discontinuing participation in research The principal investigator or co-investigator shall terminate the study if they determine that it is impossible to continue the study for any of the following reasons.
\<Termination Criteria>
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Behavioral: inhalation management education
Provide a pamphlet tailored to the patient's inhalation device.
* During interviews with researchers, undergo a technical check. Then, practice inhalation techniques. * During interviews with researchers, discuss solutions to symptoms and problems encountered in daily life. * Participants implement the solutions decided upon during the observation period. * During the second intervention, assess whether the solutions were effective and, if not, consider alternative solutions.
The Japanese version of the Pittsburgh Sleep Quality Index: PSQI-J
The PSQI-J is a questionnaire that asks about sleep patterns over the past month. It consists of 19 self-reported items and seven factors: sleep quality, sleep onset time, sleep duration, sleep efficiency, sleep difficulty, use of sleep medication, and daytime sleepiness. A total score of 0 to 3 points (0 to 21 points) is calculated, and the higher the score, the more severe the sleep disorder is considered to be.
Time frame: Baseline, 2months and 3months
Japanese Version of Epworth Sleepiness Scale:JESS
This is a self-assessment of the degree of sleepiness in eight daily-life situations. Each item is scored from 0 to 3(0-24 points), with higher total scores indicating greater daytime sleepiness. If the total score is 11 or higher, it is likely that the patient has SAS (sleep apnea syndrome).
Time frame: B0aseline, 2months and 3months
Apnea-Hypopnea Index
Apnea-Hypopnea Index(AHI) is an index used to evaluate sleep apnea syndrome (SAS). It is calculated as the total number of observed apneas and hypopneas during sleep divided by the total sleep time (typically per hour). Diagnose with sleep apnea syndrome based on AHI\>5.
Time frame: Baseline and 3 months
Depth of REM sleep
During REM sleep, estimates include the number and duration of wakefulness episodes and the proportion of REM time spent awake. The more times it occurs, the more it is considered to be disrupting sleep.
Time frame: Baseline and 3months
ODI
ODI (Oxygen Desaturation Index) is the number of oxygen desaturation events per hour of sleep. The number of events per hour in which SpO₂ drops by a certain percentage, usually 3% or 4%. Usually it's zero times.
Time frame: Baseline and 3months
Nocturnal hypoxemia
Nocturnal hypoxemia is characterized by mean overnight oxygen saturation (mean SpO₂) during sleep, minimum oxygen saturation (minimum SpO₂) observed during sleep, percentage of time with SpO2\<90%(% of total sleep time, %TST). We will investigate how much the SpO2 level decreases during a single sleep period and the duration of that decrease.
Time frame: Baseline and 3months
Arousals per hour (arousal index)
Arousals is an assessment of wakefulness events during sleep. The more times it occurs, the more it is thought to lead to a decline in sleep quality.
Time frame: Baseline and 3months
COPD assessment test: CAT
This questionnaire is designed for the simple assessment of symptoms and the impact on daily life in patients with COPD. It consists of eight items, each scored from 0 to 5. Higher scores indicate more severe symptoms and greater impact on daily life.
Time frame: Baseline, 2months and 3months
Hospital Anxiety and Depression Scale: HADS
The items are designed to be less influenced by physical symptoms, making them valid for patients with medical conditions. The total score for each is 0-21 points. A total score of 8 or more for odd numbers is considered a state of anxiety, and a total score of 11 or more for even numbers is considered a state of depression.
Time frame: Baseline, 2months and 3months
Number of technical errors
For each inhalation device, the items in which the participant performs an incorrect inhalation technique are considered errors, and the number of such items is counted.
Time frame: Baseline, 2months and 3 months
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Start is estimated for Jan 2026; primary completion for Dec 2026, 11 months later.
Of 1,099 non-industry interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 11 months is below that.
Counting every sponsor, half of 1,187 studies reached it within 22 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →
Kumamoto University